Get started
Author

Marlene C. Hinton

Observed name: Marlene Hinton
OpenAlex ID: A5073783446
Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression
2018 · Dewan Md Sakib Hossain, Sarah Javaid, et al. · Journal of Clinical Investigation · 216
Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers
2016 · Jongwon Lim, Elizabeth H. Kelley, et al. · Journal of Medicinal Chemistry · 40
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors
2012 · Weisheng Zhang, Brian B. Haines, et al. · Translational Oncology · 28
PDF
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
2016 · Amy D. Guertin, Jennifer O'Neil, et al. · Molecular Cancer Therapeutics · 21
PDF
Discovery of MK-1088 as a Potent A 2A /A 2B Adenosine Receptor Dual-Antagonist for Cancer Immunotherapy
2026 · Yonglian Zhang, Elisabeth Hennessy, et al. · Journal of Medicinal Chemistry · 2
Abstract 543: Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab
2016 · Elaine M. Pinheiro, Marlene Hinton, et al. · Cancer Research · 2
Abstract 1677: Preclinical activity of Vintafolide/MK-8109 monotherapy and in combination with standard of care therapy in triple-negative breast cancer models
2014 · Brian B. Haines, Jennifer O'Neil, et al. · Cancer Research · 1
Multi-parameter optimization of a novel anti-TROP2 MMAE antibody-drug-conjugate for solid tumor therapy
2026 · Laurence Fayadat-Dilman, Andrew B. Waight, et al. · Frontiers in Oncology
PDF
Abstract IA013: Discovery of the dual A2A/A2B receptor antagonist MK-1088 for the treatment of solid tumors
2024 · Duane E. DeMong, Sheila Ranganath, et al. · Molecular Cancer Therapeutics
Abstract 5079: Comparative studies of chemotherapy and immuno-oncology combinations in multiple mouse syngeneic tumor models
2024 · Eunsil Park, Marlene Hinton, et al. · Cancer Research
Abstract PR017: Discovery and clinical evaluation of a potent and selective A2A/2B dual receptor antagonist
2023 · Duane DeMong, Sheila Ranganath, et al. · Molecular Cancer Therapeutics
Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
2023 · Peter Georgiev, Eric S. Muise, et al.
Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
2023 · Peter Georgiev, Eric S. Muise, et al.
Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
2023 · Peter Georgiev, Eric S. Muise, et al.
Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
2023 · Peter Georgiev, Eric S. Muise, et al.
PDF
Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
2023 · Peter Georgiev, Eric S. Muise, et al.
Supplementary Figures 1-4; Supplementary Tables 1 & 2 from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
2023 · Amy D. Guertin, Jennifer O'Neil, et al.
Supplementary Figure Legends from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
2023 · Amy D. Guertin, Jennifer O'Neil, et al.
Data from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
2023 · Amy D. Guertin, Jennifer O'Neil, et al.
Data from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
2023 · Amy D. Guertin, Jennifer O'Neil, et al.
Abstract B65: High levels of expression of P-glycoprotein/multidrug resistance protein result in resistance to vintafolide
2015 · Amy D. Guertin, Jennifer O'Neil, et al. · Molecular Cancer Therapeutics
Works count: 21
Citation count: 310
H-index: 4
I10-index: 4
Year
Topic
Type